What’s in a Name: The Ongoing Saga of Medbox
It is the third week of April of 2011 and Rishi Patel is on a mission: He is taking a hard look at business opportunities in the wake of Arizona’s decision to permit the sale of medical marijuana in...
View ArticleThe Life Fantastic: Michael Saylor’s All Expense Paid World
You may not remember where you were on March 20, 2000, but it’s a very safe bet that a man named Michael Saylor does. More than 14 years later, and it’s likely still fresh in his mind because it’s not...
View ArticleThe Invention of Professor Dr. Anthony Nobles
Reader, let’s not mince any words about Dr. Anthony Nobles, a 50-year old inventor, teacher, community leader, entrepreneur and soon-to-be space tourist: his life is vastly better than yours. Hailing...
View ArticleA Reckoning for the Hedge Fund King of Akron, Ohio
Anthony Davian, a once-prolific presence on social media who held himself out as a iconoclastic hedge fund manager prior to his August 2013 indictment on a series of fraud charges, was sentenced...
View ArticleUpdate: Michael Karfunkel’s Bridge To Nowhere
It’s not everyday that someone makes a $373 million grant of shares in a company he co-founded, but on November 12 that’s exactly what the foundation of a fellow named Michael Karfunkel did when it...
View ArticleThe Past Imperfect: Mr. Neuger and Mr. Fitzmaurice Would Like Your Money, Again
The website of a new Minneapolis venture, EcoAlpha Asset Management, strikes a different chord for a hedge fund, holding itself out to the deep-pocketed as not just a way to maybe beat the market, but...
View ArticleClik here to view.
Who Owns Our Water?
Photo credit: Rohan Ayinde Smith Editor's Note: This story is the result of a collaboration between SIRF and the University of North Carolina's School of Journalism and Mass Communications Fall 2014...
View Article@Undisclosedbackstory: The Hidden History of Social Media’s Financial Gurus...
At any given moment, Joe Donahue, a cornerstone of the popular StockTwits investing community, and a veteran of a quarter century of trading, may be making another intraday call on a stock for his...
View ArticleClik here to view.
Irreproducible Results, Inc.
Editor's note: SIRF did not calculate the size of the Longwood fund (and its three partners) in OvaScience, nor its value, using the most recent documents. It is approximately 19.5 percent of the 27.12...
View ArticleClik here to view.
Insys Therapeutics and the New ‘Killing It’
On the evening of July 1, 2014, Carolyn “Suzy” Markland, a 58-year-old Jacksonville, Fla., resident with a degenerative disc disease, took her prescribed medicine -- a 400-microgram dose of a Fentanyl...
View ArticleUpdate: Mr. Neuger and Mr. Fitzmaurice decide to pursue other opportunities
Editor's note: A previous version of the story described Ron Blaylock as not investing in EcoAlpha. That is incorrect--he invested approximately $1 million. SIRF regrets the error. EcoAlpha Asset...
View ArticleClik here to view.
The Black World of Insys Therapeutics
Slowly but surely answers to the many riddles of how Insys Therapeutics could achieve its mercurial success are beginning to emerge. The Scottsdale, Ariz.-based pharmaceutical company has only one...
View ArticleSIRF Wins Lawsuit And Strikes A Sharp Blow For Journalistic Freedom
The Southern Investigative Reporting Foundation has successfully concluded a litigation arising from its September 2014 story on Southern California-based medical device entrepreneur Anthony Nobles....
View ArticleThe King’s Gambit: Valeant’s Big Secret
If the name Valeant Pharmaceuticals International doesn’t ring a bell, its business practices should. The Quebec-based drug manufacturer's policy of implementing regular price increases that often run...
View ArticleClik here to view.
The Pawn Isolated: Valeant, Philidor and the Annals of Fraud
The Southern Investigative Reporting Foundation's story looking at Valeant Pharmaceuticals' well-concealed relationship with Philidor Rx Services, struck a nerve. Briefly, the story explored the ways...
View ArticleThe Curious Case of Mr. Pearson’s 502,996 Shares
On Valeant Pharmaceutical’s conference call on November 10, embattled chief executive Michael Pearson offered several defenses of his company’s internal controls and procedures. Similarly, in defending...
View ArticleClik here to view.
Valeant’s Eastern Front
Poland seems a most unlikely place for the next chapter of Valeant Pharmaceutical's saga to play out. Weighing in at about 3% of sales, the Polish operations are seemingly a modest contributor to...
View ArticleMurder Incorporated: Insys Therapeutics, Part I
Insys Therapeutics is a company in a great deal of trouble. The manufacturer of a Fentanyl spray called Subsys with 100 times the strength of morphine, Chandler, Ariz.-based Insys scored the...
View ArticleClik here to view.
Murder Incorporated: Insys Therapeutics, Part II
The Insys that investors loved and that made its founder and chairman John Kapoor a billionaire is going away and, despite heroic efforts by company officials to rebrand it as a research and...
View ArticleClik here to view.
The Brotherhood of Thieves: Insys Therapeutics
Executives at Insys Therapeutics have continued to pressure its employees to develop new ways to mislead insurance companies into granting coverage to patients prescribed its drug Subsys, even as the...
View Article
